NeuroSense Therapeutics Ltd. (NRSN)
Automate Your Wheel Strategy on NRSN
With Tiblio's Option Bot, you can configure your own wheel strategy including NRSN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS
Published: February 18, 2026 by: PRNewsWire
Sentiment: Neutral
CAMBRIDGE, Mass., Feb. 18, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
Read More
NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition
Published: February 09, 2026 by: PRNewsWire
Sentiment: Neutral
Strengthens Global IP Portfolio for PrimeC Through 2042 CAMBRIDGE, Mass., Feb. 9, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
Read More
NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study
Published: December 22, 2025 by: PRNewsWire
Sentiment: Neutral
Clinical and Biomarker Outcomes Expected to Be Reported in Q1 2026 CAMBRIDGE, Mass. , Dec. 22, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
Read More
NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS
Published: November 24, 2025 by: PRNewsWire
Sentiment: Neutral
CAMBRIDGE, Mass. , Nov. 24, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
Read More
NeuroSense to Host Investor Webinar on December 8, 2025
Published: November 03, 2025 by: PRNewsWire
Sentiment: Neutral
Business, regulatory and clinical updates will be provided CAMBRIDGE, Mass. , Nov. 3, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
Read More
NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons
Published: September 10, 2025 by: PRNewsWire
Sentiment: Neutral
Initial Phase 2 RoAD trial results demonstrate improvements in brain-cell connectivity and health, with a favorable safety profile CAMBRIDGE, Mass. , Sept. 10, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
Read More
NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch
Published: May 07, 2025 by: PRNewsWire
Sentiment: Neutral
NeuroSense Announces Global CDMO Selection and Manufacturing Scale-Up, Enabling Rapid Pathway to Commercialization for What is Projected to be a $100-150M Canadian Market Opportunity CAMBRIDGE, Mass. , May 7, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
Read More
NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update
Published: April 24, 2025 by: PRNewsWire
Sentiment: Neutral
Letter outlines Phase 3 timeline for PrimeC in ALS, provides update on Canadian regulatory pathway and strategic partnership discussions; Company optimistic about ongoing partnership discussions with global pharmaceutical company CAMBRIDGE, Mass. , April 24, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
Read More
About NeuroSense Therapeutics Ltd. (NRSN)
- IPO Date 2021-12-09
- Website https://www.neurosense-tx.com
- Industry Biotechnology
- CEO Alon Ben-Noon
- Employees 17